机构：[1]Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Breast Center, Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[2]Functional and Molecular Imaging Key Laboratory of Sichuan Province, Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu 610041, China.[3]Xiamen Key Lab of Psychoradiology and Neuromodulation, Department of Radiology, West China Xiamen Hospital of Sichuan University, Xiamen 361021, China.
Development of novel Gd-based contrast agents for targeted magnetic resonance imaging (MRI) of liver cancer remains a great challenge. Herein we reported a novel Gd-based MRI contrast agent with improved relaxivity for specifically diagnosing liver cancer. This GSH-responsive macromolecular contrast agent (mCA), POLDGd, was prepared by RAFT polymerization, and its lactic acid moiety could precisely target the ASGP-R surface protein on liver cancer cells, whereas PODGd without the lactic acid moiety was prepared as a control. POLDGd had a high molecular weight of 45 kDa and a particle size of 103 nm. Its longitudinal relaxivity (11.39 mM-1 s-1) measured via a 3.0 T MR scanner was three times that of the clinically used contrast agent DTPA-Gd. In comparison with the PODGd-treated group, the signal enhancement at the tumor site was significantly prolonged, with a maximum enhancement peak of about 190% after intravenous injection of POLDGd into tumor-bearing mice. A high accumulation level of POLDGd in the liver tumors observed via MRI was also confirmed by fluorescence imaging. POLDGd showed minimal side effects, which may be ascribed to its metabolism through the kidneys. Therefore, POLDGd may be used as a highly effective biosafe nanoscale contrast agent for targeted MRI of liver cancer.
基金：
This research was financially supported by the Natural Science
Foundation of China (32271445), the National Key Research
and Development Program of China (2023YFB3810004 and
2022YFC2009900), the Department of Science and Technology
of Sichuan Province (2024NSFJQ0050), and the 1 3 5 project
for disciplines of excellence, West China Hospital, Sichuan
University (ZYGD23026).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
无
最新[2023]版：
大类|3 区医学
小类|3 区材料科学：生物材料
第一作者：
第一作者机构：[1]Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Breast Center, Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Breast Center, Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China[2]Functional and Molecular Imaging Key Laboratory of Sichuan Province, Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Chen Jie,Wang Xiaoming,Bai Yinan,et al.An ASGP-R-targeting magnetic resonance imaging contrast agent for liver cancer diagnosis[J].Journal Of Materials Chemistry. B.2025,doi:10.1039/d4tb02708f.
APA：
Chen Jie,Wang Xiaoming,Bai Yinan,Li Zhiqian,Li Haonan...&Luo Kui.(2025).An ASGP-R-targeting magnetic resonance imaging contrast agent for liver cancer diagnosis.Journal Of Materials Chemistry. B,,
MLA：
Chen Jie,et al."An ASGP-R-targeting magnetic resonance imaging contrast agent for liver cancer diagnosis".Journal Of Materials Chemistry. B .(2025)
